Trenkwalder P, Schaetzl R, Borbas E, Handrock R, Klebs S
Department of Internal Medicine, Starnberg Hospital, Starnberg, Germany.
Blood Press Suppl. 2008 Dec;2:13-21. doi: 10.1080/08038020802488855.
This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg.
Of 133 patients treated for 5 weeks with ramipril 5 mg and felodipine 5 mg, 105 failed to achieve mean sitting systolic blood pressure <140 mmHg. These non-responders were then treated for an additional 5 weeks with amlodipine 10 mg and valsartan 160 mg, which resulted in clinically and statistically significant additional reductions in mean sitting systolic blood pressure of 15.4 mmHg (p<0.0001) and mean sitting diastolic blood pressure of 7.0 mmHg (p<0.0001). Adverse event rates were low with both treatment regimens.
In hypertensive patients not controlled at 5 weeks by ramipril 5 mg and felodipine 5 mg, significant additional blood pressure reductions were observed after 5 weeks of treatment with amlodipine 10 mg and valsartan 160 mg. The combination of amlodipine 10 mg and valsartan 160 mg was well tolerated.
本多中心、开放标签、单臂试验评估了氨氯地平10毫克与缬沙坦160毫克联合用药在血压控制不佳的中度高血压患者中的疗效，这些患者对赖诺普利5毫克与非洛地平5毫克联合用药反应欠佳。
133例接受赖诺普利5毫克与非洛地平5毫克治疗5周的患者中，105例未能使平均坐位收缩压降至<140 mmHg。这些未达标患者随后接受氨氯地平10毫克与缬沙坦160毫克治疗5周，结果显示平均坐位收缩压在临床和统计学上显著进一步降低15.4 mmHg（p<0.0001），平均坐位舒张压进一步降低7.0 mmHg（p<0.0001）。两种治疗方案的不良事件发生率均较低。
在接受赖诺普利5毫克与非洛地平5毫克治疗5周血压仍未得到控制的高血压患者中，使用氨氯地平10毫克与缬沙坦160毫克治疗5周后，血压显著进一步降低。氨氯地平10毫克与缬沙坦160毫克联合用药耐受性良好。
